584 reports of this reaction
4.2% of all AZELASTINE HYDROCHLORIDE reports
#2 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #2 most commonly reported adverse reaction for AZELASTINE HYDROCHLORIDE, manufactured by Alembic Pharmaceuticals Limited. There are 584 FDA adverse event reports linking AZELASTINE HYDROCHLORIDE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 4.2% of all 14,064 adverse event reports for this drug.
Patients taking AZELASTINE HYDROCHLORIDE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among AZELASTINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for AZELASTINE HYDROCHLORIDE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 584 FDA reports for AZELASTINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 4.2% of all adverse event reports for AZELASTINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience product dose omission issue while taking AZELASTINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.